OncoMatch/Breast Cancer/BRCA1
Breast CancerBRCA1 Clinical Trials
Germline BRCA1 pathogenic variants account for 3–5% of all breast cancers and are enriched in TNBC and high-grade tumors with specific DNA repair vulnerabilities. Olaparib and talazoparib — PARP inhibitors — are FDA-approved for germline BRCA1/2-positive HER2-negative metastatic breast cancer. Trials investigate PARP inhibitor combinations with immunotherapy, platinum chemotherapy, antibody-drug conjugates, and neoadjuvant strategies.
Top recruiting BRCA1 Breast Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
Cambridge University Hospitals NHS Foundation Trust
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Massachusetts General Hospital
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
GBG Forschungs GmbH
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
Erasmus Medical Center
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
More BRCA1 Breast Cancer trials
3 international trials (no US sites)
Browse other molecular targets with active Breast Cancer trials.